Menu
Share this

PPD to Present at Second Annual World Pharma Trials

Simon Britton to share insights on growth of clinical research in Asia

15 Mar. 2010

RSS

WILMINGTON, N.C. (March 15, 2010) - PPD, Inc. (Nasdaq: PPDI) today announced Simon Britton, vice president of clinical development, Asia Pacific, is a guest speaker at the World Pharma Trials 2010 conference in Singapore. His presentation will address the effectiveness of Asia's people, infrastructure and CROs in supporting the region's growing drug development activities. PPD is a silver sponsor of this year's event.

Britton will join a panel of experts in analyzing supply versus demand of investigator sites, clinical trial experts, qualified partners and other drug development resources in Asia. The panel will also evaluate how well Asia is handling the increase of global biopharmaceutical companies moving their drug development programs into the region and innovative strategies to access untapped emerging countries. The presentation is Wednesday, March 17, at 11:55 a.m. UTC.

Britton provides strategic leadership for PPD's clinical research business throughout Asia Pacific and plays an integral role in the company's growth and development in the region.

PPD is one of the largest CROs in Asia Pacific with more than 1,400 employees and offices in 10 countries. In 2009, PPD acquired Excel PharmaStudies and BioDuro, strengthening its full range of drug discovery and development services and ability to provide scientific and technical expertise, global reach and a local understanding of clinical research in the region.

World Pharma Trials Asia brings together leaders from biopharmaceutical companies and CROs to explore a broad range of offshoring and outsourcing topics. The Asia drug development market is doubling in size each year as more global pharmaceutical companies conduct their clinical research programs in this growing region.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the value of the information presented during this presentation are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: continued success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; competition within the outsourcing industry; the ability to attract and retain key personnel; risks associated with and dependence on collaborative relationships; risks associated with the development and commercialization of drugs, including earnings dilution and obtaining regulatory approval; risks associated with acquisitions and investments, such as impairments; rapid technological advances that make our products and services less competitive; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contact Us

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
PPD
Tel: +1 919 456 4425

Elizabeth Humphrey Corporate Communications Manager
PPD
Tel: +1 910 558 6096

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2017 Pharmaceutical Product Development, LLC. All rights reserved.